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ABSTRACT
Despite recent therapeutic advances, multiple myeloma (MM) is still an incurable 
neoplasia due to intrinsic or acquired resistance to therapy. Myeloma cell localization 
in the bone marrow milieu allows direct interactions between tumor cells and non-
tumor bone marrow cells which promote neoplastic cell growth, survival, bone 
disease, acquisition of drug resistance and consequent relapse. Twenty percent of 
MM patients are at high-risk of treatment failure as defined by tumor markers or 
presentation as plasma cell leukemia. Cumulative evidences indicate a key role of 
Notch signaling in multiple myeloma onset and progression. Unlike other Notch-
related malignancies, where the majority of patients carry gain-of-function mutations 
in Notch pathway members, in MM cell Notch signaling is aberrantly activated due 
to an increased expression of Notch receptors and ligands; notably, this also results 
in the activation of Notch signaling in surrounding stromal cells which contributes 
to myeloma cell proliferation, survival and migration, as well as to bone disease and 
intrinsic and acquired pharmacological resistance. Here we review the last findings on 
the mechanisms and the effects of Notch signaling dysregulation in MM and provide 
a rationale for a therapeutic strategy aiming at inhibiting Notch signaling, along with 
a complete overview on the currently available Notch-directed approaches.
MULTIPLE MYELOMA
Multiple Myeloma (MM) is a hematological 
malignancy characterized by a malignant proliferation 
of bone marrow (BM) post-germinal center plasma 
cells (PCs) and release of monoclonal protein in blood 
or urine. MM accounts for 1% of all neoplastic disease 
and represents 13% of hematologic cancers. In Western 
countries, its annual incidence is approximately 5.6 cases 
per 100.000 individuals. The median age at diagnosis is 
about 70 years [1, 2].
MM represents a highly biologically and clinically 
heterogeneous neoplasia; it shows four distinguishable 
clinical phases that, however, may not be discernible 
in each patient (Figure 1). MM may be preceded by a 
monoclonal gammopathy of undetermined significance 
(MGUS), an indolent, asymptomatic, premalignant 
phase characterized by a small clonal population (<10%) 
of PCs within the BM. MGUS may progress to MM at 
a rate of 1% per year. Intramedullary MM may present 
as an asymptomatic, smoldering, multiple myeloma 
(SMM), or associated with organ dysfunction including 
hypercalcemia, renal failure, anemia, and bone disease. 
SMM has an average risk of progression to MM of 10% 
per year [3,4]. The final stage of MM is represented by 
the plasma cell leukemia (PCL), defined as at least 20% 
of PCs or an absolute PCs count of more than 2 × 109/L 
in the peripheral blood. PCL is a rapidly progressive and 
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fatal disease which may occur as secondary (sPCL) in 
the context of a preexisting refractory MM, or primary 
(pPCL) if presenting de novo in leukemic phase [5,6].
In the last decade, important advances in molecular 
cytogenetics and global genomic studies of myeloma cells 
and their normal counterparts have allowed a significant 
progress in understanding MM pathogenesis, providing 
the basis for a molecular prognostic classification and the 
identification of novel potential therapeutic targets. MM 
is characterized by a profound genomic instability that 
involves both ploidy and structural rearrangements. Nearly 
half of MM tumors are defined as hyperdiploid (HD) 
associated with trisomies of odd chromosomes (including 
3, 5, 7, 9, 11, 15, 19, and 21). The remaining tumors are 
referred as non-hyperdiploid and are frequently associated 
with the constitutive activation of CCND1 (11q13), 
CCND3 (6p21), MAF (16q23), MAFB (20q11), or FGFR3/
MMSET (4p16.3) genes as a result of IGH translocations. 
Generally, HD patients have a better prognosis [7, 8]. 
Recent data based on whole exome/genome sequencing 
indicated a heterogeneous pattern of gene mutations in 
MM, frequently involving member of the ERK pathway 
(NRAS, KRAS or BRAF) and, at a lesser extent, other genes 
such as DIS3 or FAM46c [8–11].
MM is associated with bone disease in more than 
80% of MM patients, due to osteoclast-mediated bone 
destruction which causes hypercalcemia, osteoporosis, 
bone pain and fractures [12]. In particular, up to 70% of 
patients have vertebral fractures, which are associated 
with a high impairment of quality of life, morbidity and 
mortality [12]. Bone resorption is not only a relevant issue 
for patients quality of life, but represents also a critical 
step in the development of this disease, since it supports 
tumor growth and survival and finally contributes to the 
development of drug resistance [13, 14].
High incidence of bone lesions in MM patients 
is due to the ability of malignant PCs to alter the ratio 
between osteoclasts (OCLs) and osteoblasts (OBLs) 
in favor of the first [13, 15]. This effect is mediated by 
an increase of BM-associated anti-osteoblastogenic 
factors, such as DKK1, IL3, IL7 and TGF-β [11], or 
pro-osteoclastogenic factors, such as TNFα and RANKL 
[16, 17, 18]. Importantly, MM cells play a key role in 
inducing bone disease directly or indirectly, i.e. MM cells 
may autonomously produce RANKL [16] or stimulate 
the surrounding BM cells to release RANKL and other 
soluble factors that promote OCL differentiation [18]. 
OCLs directly support MM cell proliferation and survival, 
leading to disease progression [19].
Thus, malignant transformation in MM represents 
a multistep process due to accumulating genetic and 
epigenetic alterations of PCs as well as to their aberrant 
interactions with BM microenvironment.
The use of novel therapeutic agents such as 
immunomodulators (i.e. thalidomide and lenalidomide) 
and proteasome inhibitors (bortezomib), as well as the 
incorporation of high-dose chemotherapy followed 
by autologous stem cell transplantation represents the 
current therapy for MM patients up to 65 years old, 
without comorbidities and organ dysfunction [1, 20, 
21]. Conventional chemotherapy (such as melphalan) 
combined with novel therapeutic drugs is generally 
administered in patients older than 65 years or unfit [22]. 
Recently, two different groups of new generation drugs 
Figure 1: Schematic representation of MM progression and oncogenic events along the four clinical phases: MGUS, 
SMM, MM, PCL. See details in the text.
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have been developed; these include novel proteasome 
inhibitors (carfilzomib, ixazomib and marizomib) 
and drugs with novel mechanisms of action such as 
monoclonal antibodies, specific inhibitors of signaling 
pathways and kinases, deacetylase inhibitors and agents 
activating the unfolded protein response, especially Hsp90 
inhibitors [23]. Nowadays, the median overall survival of 
MM patients is 7–8 years [1].
However, despite the recent remarkable 
improvements in the treatment of patients and the 
development of investigational platforms, MM remains 
still incurable mainly because of intrinsic or acquired 
drug resistance. MM cells localization in the BM milieu 
allows the direct interaction with non-tumor BM cells 
that provide several stimuli promoting neoplastic cell 
growth and drug resistance, and consequently patient’s 
relapse [24]. In addition, approximately twenty percent of 
patients at diagnosis are at high-risk of treatment failure 
defined by prognostic markers or due to presentation 
as PCL. The following chromosomal aberrations 
have been associated with an adverse outcome: 
i) translocation t(4;14) in 15% patients, which deranges 
the expression of FGFR3 (a receptor tyrosine kinase) 
and multiple myeloma SET domain (MMSET; a histone 
methyltransferase acting as a transcriptional corepressor); 
ii) translocations t(14;16) and t(14;20) which affects 
approximately 6% patients resulting in the upregulation 
of oncogenes c-MAF and MAFB, respectively; iii) the 
deletion of the short arm of chromosome 17 (del17p) 
observed in 10% of newly diagnosed MM patients and 
increasing with MM progression, which results in the loss 
of TP53 hampering its role in the control of cell cycle and 
survival; iv) the gain of the long arm of chromosome 1 
which is found in approximately 40% of patients at onset 
and results in gene amplification of PDZK1, CKS1B and 
ADAR1 [7–9]. It has been shown that PDZK1 plays a 
role in conferring drug resistance to MM cells, whereas 
CSK1B promotes MM cell proliferation and drug 
resistance through JAK/STAT3 and MEK/ERK [25]. 
ADAR1 may play a role in tumor progression through 
its activities of RNA editing, microRNA processing 
and RNA-induced gene silencing, possibly resulting in 
malignant reprogramming [26–27].
NOTCH SIGNALING PATHWAY
A strain of Drosophila characterized by wings 
with irregular, “notched” margins was discovered in 
1919 and lately associated to haploinsufficiency in the 
Notch gene [28]. In mammals, the Notch family of 
genes is composed by four transmembrane receptors, 
characterized by highly homologue sequences (Notch1–4), 
and two closely related families of membrane-
bound ligands: the Delta-like ligands (DLL1, 3, 4) 
and the Serrate-like ligands (Jagged1 and 2) [29]. The 
interaction between receptors and ligands induces two 
proteolytic cleavages, the release of the cytoplasmic portion 
and the translocation to the nucleus of the active form of 
Notch (intra-cellular Notch, ICN) [29].
The Notch pathway regulates cell differentiation, 
apoptosis, proliferation, morphogenesis and it is 
essential for embryonic development of multicellular 
organisms [30]. Specifically, in mammals Notch is able 
to regulate various processes such as vasculogenesis, 
myogenesis, gliogenesis, neurogenesis and hematopoiesis 
[29]. Moreover, the Notch pathway is also involved 
in the homeostasis of adult tissues by regulating cell 
differentiation [30], promoting stem cells self-renewal [31]
and determining cell fate choice in tissue development, 
including the commitment to T and B cell lineages [32]. 
The involvement of Notch signaling in the regulation of 
these important processes may explain the occurrence 
of the deregulation of Notch receptors or ligands in 
several types of cancer, including solid (i.e. breast cancer, 
melanoma, colorectal cancer, glioblastoma, pancreatic 
cancer) [33] and hematologic tumors (i.e. T-ALL, B-ALL, 
AML, B-CLL, MM) [34–37].
THE NOTCH PATHWAY: A KEY 
MEDIATOR OF MM PROGRESSION
Notch signaling dysregulation in MM can be 
ascribed to the overexpression of both receptors and 
ligands (Table 1). In particular, immunohistochemical 
analyses revealed that Notch1, Notch2 and Jagged1 
are highly expressed in primary MM cells compared to 
low/undetectable levels in non-neoplastic counterparts 
[38]. Furthermore the increase of Notch1 and Jagged1 
expression was reported upon disease progression 
from MGUS to MM [39]. NOTCH2 gene expression 
levels and activity were reported to be increased in the 
group of MM patients (approximately 6%) carrying the 
translocations t(14;16)(q32;q23) and t(14;20)(q32;q11) 
[40]. These translocations result in the activation of two 
transcription factors (C-MAF and MAFB respectively), 
responsible of NOTCH2 transcription [40]. Jagged2 
deregulation seems an even more essential step in 
MM pathogenesis since its overexpression is an early 
event occurring in the benign MGUS phase [41]. The 
mechanisms involved in Jagged2 dysregulation are 
complex and include Jagged2 promoter hypomethylation 
[41], the aberrant expression of Skeletrophin, an 
Ubiquitin-ligase necessary for Jagged2 activity [42], 
and the loss of SMRT/NCoR2 corepressor which 
results in Jagged2 promoter acetylation and increased 
transcription [43].
Finally, with regard to Notch signaling dysregulation 
in MM, it can be noted that “hyperdiploid” cases are 
associated with trisomies of different chromosomes [44] at 
which genes belonging to Notch pathway, such as NOTCH1 
(chr.9q34.3), NOTCH3 (19p13.2–p13.1), DLL3 (19q13), 
DLL4 (15q14), MAML1 (5q35), and MAML2 (11q21), are 
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located. Moreover, high levels of HES5, a direct Notch 
transcriptional target [45], have been reported in the 
subgroup of LB patients (low bone disease) [44]. Although 
these evidences suggest a possible increase of Notch activity 
in these tumors, they should be further corroborated by a 
thorough molecular analysis of the expression of Notch 
signaling members in MM patients subgroups.
The first outcome of Notch receptors and ligands 
dysregulation in MM is the activation of Notch signaling 
within tumor cell due to homotypic interaction among 
nearby myeloma cells or to the engagement of Notch 
receptors by ligands expressed on the surrounding stromal 
cells (see scheme in Figure 2). Several reports indicate that 
Notch inhibition in MM cells induces apoptosis, decreases 
proliferation rate [46, 47] and increases their sensitivity to 
pro-apoptotic compounds such as Bcl-2/Bcl-XL inhibitors 
[48]. Moreover, Notch blockade causes an increase of 
MM cells sensitivity to standard chemotherapics such 
as doxorubicin and melphalan both in vitro and in vivo, 
finally preventing the development of BM-derived drug 
resistance [47]. We also showed a role for Notch in the 
directional migration of MM cell [46] in analogy to other 
healthy and neoplastic cell types [49–52]. In particular, 
Notch signaling controls the expression and function of 
the CXCR4/SDF1α chemokine system, which is crucial 
in malignant PC growth, survival and migration [46]. 
Accordingly, in vivo inhibition of Notch activity in a 
xenograft murine model of MM results in the reduction 
of CXCR4 expression in MM cells and in a consequent 
significant decrease of MM cell localization to the BM, the 
primary source of SDF1α chemokine [46]. The evidence 
that Notch signaling dysregulation may drive MM cell 
localization at the BM strongly suggests that the increase 
of Notch signaling activity during MM progression may 
promote the continuous migration of MM cells from the 
initially infiltrated BM site to different bone districts, 
resulting in the formation of multiple bone lesions.
In the last years, another crucial role for Notch 
signaling has been reported in cancer stem cell self-
renewal [53]. The proposed involvement of MM stem 
cells (MMSCs) in drug resistance, tumor dormancy 
and relapse has drawn the attention of the scientific 
community on the identification of specific MMSC 
markers. Unfortunately, up to now, there are not univocal 
MMSC markers. Indeed, it is still a matter of debate 
whether MMSCs originate from B cells, and therefore can 
be identified as CD138−CD19+CD20+ cells [53], or if 
they derive from mature plasma cells, which can be found 
in the CD138+ population [55]. Moreover it cannot be 
excluded that different MMSC subpopulations rise during 
MM progression. Even though the lack of unambiguous 
markers makes the study of MMSCs difficult, a role of 
Notch signaling in MMSCs has been described on the 
basis of functional assays [56, 57]. Xu and colleagues 
reported that MS5 stromal cell line, genetically modified 
to have a high constitutive expression of human DLL1, 
increased human and murine MM cells clonogenic 
growth in vitro and accelerated disease development in 
the 5T33MM murine model [56]. Chiron et al. reported 
that Jagged2 is critical for MM cell self-renewal, showing 
that spontaneous clonogenic growth of MM cell lines 
correlated with the expression of Jagged2, whereas on the 
other end, clonogenic and in vivo growth was impaired 
by Jagged2 silencing [57]. Overall these results suggest 
that the activation of Notch signaling pathway, mediated 
by the overexpression of Notch receptors or ligands, 
may have a key role in promoting MM progression and 
maintenance.
On the other side, Notch signaling in MM cells 
can be also activated by Notch ligands expressed on 
the surface membrane of surrounding BM cells (see 
scheme in Figure 2). Xu et al. demonstrated that BMSCs 
expressed DLL1 and were able to engage Notch2 in MM 
cells. In turn, Notch2 activation caused the upregulation 
of CYP1A1 (cytochrome P450, family 1, subfamily 
A, polypeptide 1), contributing to the development of 
resistance to treatment with bortezomib [58]. Interestingly, 
the combined treatment with a Notch-blocking agent and 
Table 1: Alterations of Notch pathway in multiple myeloma
Deregulation type Phase Mechanism Reference
Notch1/Jagged1 expression Progression from MGUS to MM unknown (39)
Notch2 overexpression MM Transactivation by MAF genes due to t(14;16) (q32;q23) and t(14;20)(q32;q11) (40)
Jagged2 overexpression Since MGUS
Gene expression deregulation due to promoter 
hypomethylation or loss of SMRT/NCoR2 corepressor. 
Increased ligand ubiquitination and activity due to 
aberrant expression of Skeletrophin
(41–43)
HES5 overexpression MM (LB subgroup) unknown (44)
Increased copy number of 
Notch pathway members MM (HY subgroup)
Possible mechanism: trisomies of chromosomes 3, 5, 7, 
9, 11, 15, 19 and 21 (44)
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bortezomib leads to an increase sensitivity to bortezomib 
resulting in a significant improvement of the overall 
survival in an in vivo model of MM [58].
A second and important outcome of Notch receptors 
and ligands dysregulation in MM concerns the ability of 
MM cells to shape the BM niche (see scheme in Figure 3). 
Jagged2 increases the release of soluble factors including 
interleukin 6 (IL6), vascular endothelial growth factor 
(VEGF) and insulin-like growth factor 1 (IGF1) from 
BMSCs [41]. The released factors have a recognized 
promoting activity for MM. Indeed, IL6 is the major 
growth factor for MM cells [59], also involved in the 
development of resistance to dexamethasone in vitro [60]. 
This is further confirmed by the evidence that Siltuximab, 
an anti-IL6 monoclonal antibody, gives promising 
results alone or in combination with dexamethasone in 
a phase 2 clinical trial on patients with refractory MM 
[61]. VEGF promotes MM cell growth [62] as well as 
neo-angiogenesis [63], thereby directly and indirectly 
promoting tumor burden and progression of MM [64]. 
IGF1 promotes survival in MM cell and development of 
bortezomib resistance [65].
Notch signaling dysregulation in MM plays also 
a role in MM-associated bone disease, contributing to 
the unbalance between OCLs and OBLs in favor of the 
first (see scheme in Figure 4). We recently dissected the 
different effects due to Notch signaling dysregulation in 
MM-induced osteoclastogenesis and bone resorption. In 
particular we showed that: i) high Notch signaling in MM 
cells stimulates the release of the major osteoclastogenic 
soluble factor, RANKL; ii) MM cell-derived Notch 
ligands (Jagged1 and 2) activate Notch signaling in 
surrounding BMSCs, boosting the secretion of RANKL; 
iii) RANKL engages RANK on OCL progenitors, thereby 
activating the osteoclastogenic NF-kB pathway, which in 
turn stimulates the osteoclastogenic Notch signaling by 
promoting Notch2 expression; and iv) MM cell-derived 
Jagged ligands further boost Notch signaling in OCL 
progenitors by engaging Notch2. Notably, Jagged1/2 
silencing is able to revert these effects [66].
Notch hyperactivity in MM may also affect OBL 
development. Zanotti and co-workers demonstrated in 
transgenic mice that the selective Notch activation in 
OBL progenitors inhibits their differentiation [67]. This 
suggests that MM cell-derived Notch ligands can also be 
responsible for the decrease of OBLs by stimulating Notch 
activity that hampers OBL progenitors differentiation.
These results, confirmed in vivo by the experiments 
of Schwarzer and colleagues [68] with γ-secretase 
inhibitors (GSIs), suggest that the Notch pathway 
may represent a suitable target for the treatment of 
MM-associated bone disease. Moreover, the tight 
cooperation of Notch and NF-kB pathways (mediated by 
RANKL) in MM-induced osteoclastogenesis suggests 
that a combination treatment of Notch and proteasome 
inhibitors could be even more effective. Interestingly, this 
Figure 2: Homotypic and heterotypic activation of the Notch signaling in MM cells. Biological effects and molecular effectors 
activated by Notch signaling in MM cell. See text for details.
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combined approach could not only affect osteolysis, but 
also overcome MM-associated drug resistance. Indeed, as 
reported by Xu and coworkers, GSI-mediated inhibition of 
Notch2 in MM cell increases the sensitivity to bortezomib 
[58]. These findings provide a rationale for a combined 
treatment with Notch and proteasome inhibitors that could 
synergistically prevent bone disease and drug resistance. 
Taken together the data reported above suggest that the 
Figure 3: BMSC-mediated heterotypic activation of the Notch signaling in MM cells. Biological effects and molecular 
effectors involved. See text for details.
Figure 4: Notch hyperactivation drives the unbalancing of OBLs and OCLs activity, promoting the development of 
MM-associated bone disease. See text for details.
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Notch pathway may represent a rational target for MM 
therapy, alone or in combination with standard of care 
chemotherapics.
NOTCH TARGETED THERAPIES: 
STATE OF THE ART AND FUTURE 
PERSPECTIVES
As reported, Notch signaling alterations described in 
MM result in an increased expression of Notch pathway 
members including receptors and ligands [42]. These 
alterations cause a moderate increase of Notch signaling in 
comparison to Notch pathway hyperactivation occurring 
in other types of cancer characterized by gain-of-function 
Notch mutations, i.e. T-ALL [36], other lymphoid 
malignancies [34] and solid tumors, including breast 
cancer [69], ovarian cancer [70] and esophageal squamous 
cell carcinoma [71]. It must also be noted that if a moderate 
activation of Notch has a pro-tumor effect in MM cells, a 
stronger activation due to a mutated constitutively active 
Notch results in MM cell growth inhibition and apoptosis 
[72]. Recently, Kannan and colleagues [73] provided 
a possible explanation for this behavior, revealing that 
the transcription of the Notch target Hairy/Enhancer of 
Split1 (HES1), occurring upon Notch activation, may 
have a different outcome depending on the relative levels 
of HES1 and Poly ADP-Ribose Polymerase1 (PARP1). 
Indeed, the interaction between HES1 and PARP1 inhibits 
HES1 growth promoting function and induces PARP1 
activation resulting in consequent apoptosis. Consistently, 
T-ALL cells that carry mutated hyperactive Notch1 
and low levels of PARP1 display high levels of cell 
proliferation and do not undergo apoptosis. Concerning 
MM cells, we can speculate that, similarly to B-ALL cells, 
they cannot bear high Notch signaling activation due to the 
relatively high expression of PARP1 [73].
Although MM cell growth is affected not only 
by Notch withdrawal but also by its hyperactivation, a 
therapeutic approach based on Notch inhibition appears to 
be safer in consideration of the oncogenic activity of Notch 
in several cell types. A therapeutic approach directed 
to inhibit Notch signaling in MM relies on previously 
detailed in vitro and in vivo evidences of the outcomes of 
Notch signaling inhibition, including decreased MM cell 
proliferation [46, 47], stemness [56, 57], migration and 
BM infiltration [46], MM-associated bone disease [66–68] 
and an increased sensibility to pharmacological treatments 
[47, 48, 58].
On the other side, despite the critical role of Notch 
signaling in MM, the wide genetic heterogeneity might 
give origin to molecular MM subtypes with different 
sensibilities to an anti-Notch treatment.
Although a more comprehensive analysis should be 
addressed to define the putative MM patients who could 
benefit from a Notch-targeted approach by correlating 
the molecular characterization and the outcome of Notch 
withdrawal in primary cells, we can speculate that a 
suitable subgroup could be MM patients with MAF 
translocations and consequent high Notch2 levels [40]. 
A complete gene expression analysis of Notch pathway 
members could help in evaluating if other patients 
subgroups (i.e. LB and HY; ref. 44) could be possible 
candidates for a Notch tailored therapy.
Another aspect that should be considered is 
the possible resistance of MM cells to anti-Notch 
treatment. GSI-resistance, caused by mutations occurring 
in downstream Notch mediators or by epigenetic 
mechanisms, is well described in T-ALL [74, 75, 76], 
nonetheless up to now it has not been reported in 
MM cells.
A Notch-directed therapy in MM can get advantage 
by the recent development of several compounds targeting 
the different components of the Notch pathway (Table 2). 
The most widely used drugs inducing Notch withdrawal 
are the GSIs. The γ-secretase complex is responsible 
for the proteolytic cleavage that allows the intracellular 
portion of the Notch receptor to translocate to the nucleus 
and activate the transcription by the CSL (CBF1/RBP-J, 
Su(H), Lag1) nuclear factor [77]. We report the outcome 
of different GSIs in clinical trials for cancer therapy.
MK0752 (Merck Chemicals Ltd) is a powerful non-
competitive oral GSI and represents the clinical analogues 
of the compound MRK003. MRK003 has cytotoxic and 
pro-apoptotic effects on non-Hodgkin lymphoma and 
MM cells in vitro and ex vivo and is able to overcome the 
protective effects of BMSCs [78]; it gave also promising 
results on in vivo xenograft models of uterine serous 
carcinoma and breast cancer [79, 80]. In the last years, 
MK0752 has been clinically tested for T-ALL treatment 
with poor results [81], while a trial on patients with 
metastatic or locally advanced breast cancer or advanced 
solid tumors, using intermittent MK0752 dosage, resulted 
in Notch pathway inhibition associated to good tolerability 
and clinical benefits (ref. 82; Trial ID NCT00106145).
Recently, MK0752 has been studied in combination 
with other chemotherapics. A combination with tamoxifen 
or letrozole gave promising results in the treatment of 
early stage hormone receptor-positive breast cancer (ref. 
83; Trial ID NCT00756717), while a combination with 
docetaxel has been used for the treatment of patients 
with locally advanced or metastatic breast cancer and 
resulted effective in the depletion of the cancer stem cell 
population (ref. 84; Trial ID NCT00645333).
PF-03084014 (Pfizer Oncology) is a small non-
competitive and reversible GSI. This compound has 
shown a significant antitumor activity in several T-ALL 
cell lines [85] and in breast cancer xenograft mice [86]. 
Moreover, PF-03084014 in combination with fludarabine 
displayed a synergistic effect on cell proliferation and 
chemotactic response of primary chronic lymphocytic 
leukemia cells  [87]. PF-03084014 is currently tested 
in phase 1 trial in patients with advanced solid tumors 
(ref. 88; Trial ID NCT01286467).
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RO4929097 (Roche) was tested in phase I study with 
positive results in single cases of metastatic melanoma, 
colorectal adenocarcinoma, epithelioid sarcoma out of 
92 patients with advanced solid tumors [89]. In phase II 
clinical trial involving patients with metastatic colorectal 
cancer, RO4929097 did not change radiographic response 
and time to progression at the used dose and schedule 
(ref. 90; Trial ID NCT01116687).
RO4929097 was also tested in combination with 
different chemotherapics or targeting agents like cediranib 
(VEGF inhibitor; ref. 91; Trial ID NCT01131234), 
temsirolimus (a mTOR inhibitor; ref. 92; Trial ID 
NCT01198184) and gemcitabine (ref. 93; Trial ID 
NCT01145456). These combination studies, despite the 
presence of a high percentage (~50–70%) of patients with 
stable disease, resulted in the reciprocal interference of the 
used drugs causing the interruption of trials [94].
Independently from their efficacy, the most relevant 
objection for the use of GSIs is that these drugs do 
not exclusively target the Notch pathway. Indeed, the 
GSIs affect γ-secretase which regulates the functions of 
several substrates such as E-cadherin, N-cadherin [95] 
and syndecan-3, ErbB4 and CD44 [96]. Moreover, GSIs 
inhibit the activation of all the four Notch isoforms, 
thereby affecting all the physiologic functions mediated 
by the Notch pathway. This may explain the presence of 
relevant adverse events as fatigue, skin disorders, headache, 
hypophosphatemia and severe gastrointestinal toxicity [89]. 
Gut toxicity is the most serious GSI-associated side effect, 
due to goblet cell metaplasia in the intestinal crypts [97].
Attempts to decrease GSIs toxicity without 
affecting their efficacy had some successful results using 
an intermitting dosage schedule in combination with 
corticosteroids [94]. Additionally, in the last years, new 
generation drugs were developed for a more specific 
Notch directed therapy with the purpose of overcoming 
GSI toxicity. Indeed, recent findings encourage the use of 
approaches directed to selectively inhibit Notch receptors 
or ligands. As a matter of fact, whereas it is recognized 
that the inhibition of both Notch1 and Notch2 induces 
intestinal goblet cell metaplasia [98] resulting in a major 
gastrointestinal toxicity, a recent report indicates that this 
side effect can be avoided through the selective inhibition 
of Notch signaling activation mediated only by one Notch 
receptor or one family of Notch ligands (Jagged or DLL). 
Indeed, antibodies against Notch1 or Notch2 [99], or Notch 
decoy molecules that selectively disrupt Notch/Jagged 
or Notch/DLL interaction [100], did not or mildly affect 
intestine differentiation.
In general, compounds for Notch directed-therapy 
may be divided into two classes: monoclonal antibodies 
and molecular drugs.
Monoclonal antibodies
Monoclonal antibodies (mAbs) were recently 
developed against both Notch receptors and ligands. 
mAbs are specific for single members of the Notch family; 
nonetheless their delivery in solid tumors can be highly 
problematic, due to their high molecular weight. Thus, 
anti-Notch antibodies are more frequently used in studies 
on hematopoietic malignancies [101]. Notch targeting 
mAbs have entered into early phase clinical development 
as reported below.
OMP-59R5 (Tarextumab, OncoMed 
Pharmaceuticals-GlaxoSmithKline) is a fully humanized 
antibody that targets Notch-2 and 3 receptors [102]. It was 
tested in combination with nab-paclitaxel and gemcitabine 
in a still ongoing trial on patients with untreated metastatic 
pancreatic cancer and other epithelial tumors giving 
preliminary promising results (Trial ID NCT01647828). 
Phase I clinical studies are also conducted on advanced 
solid tumors (Trial ID NCT01277146) and untreated 
extensive-stage small-cell lung cancer (ref.103; Trial ID 
NCT01859741).
OMP-52M51 (Anti-Notch1, OncoMed 
Pharmaceuticals-GlaxoSmithKline) is a novel antibody 
specific for Notch-1 that blocks the activation of this 
receptor by binding its negative regulatory region. It 
was shown to improve the survival of T-ALL xenograft 
mice [104] and it is currently under study in two Phase 
I clinical trials in advanced lymphoid malignancies 
(NCT01703572) and in solid cancers (NCT01778439). 
OMP-52M51 and OMP-59R5 have not been tested yet 
for MM treatment, although they promise to be effective 
on patients characterized by high levels of Notch1 and 
Notch2 expression.
OMP-21M18 (Demcizumab, OncoMed 
Pharmaceuticals), REGN421/SAR153192 (Enoticumab, 
Regeneron Pharmaceuticals) are humanized antibody-
based drugs against the Notch ligand DLL4, which is 
key in vessels formation [105]. These novel drugs have 
been developed and successfully tested to contrast tumor-
associated angiogenesis giving promising results in 
phase I clinical trials on advanced solid tumors, causing 
a reduction in tumor size with a general good tolerability 
(ref. 106, Trial ID NCT00744562; ref. 107, Trial 
ID NCT00871559).
The evidence that angiogenesis is increased in 
the BM of MM patients in correlation with MM cell 
infiltration, growth and survival [64], provides the rational 
for a DLL4-based anti-angiogenic therapy in this tumor; 
nonetheless it must be noted that trials with bevacizumab 
in MM [108] gave limited results and do not encourage an 
anti-angiogenic approach in MM.
Recent data in the literature highlight the possibility 
of affecting other biological features including drug 
resistance and bone disease by targeting Notch ligands 
in MM. Several evidences justify a therapeutic approach 
directed to Notch ligands. Indeed, BMSC-derived DLL1 
promotes MM cells growth and resistance to bortezomib 
[56, 58], Jagged2 overexpression in MM may induce 
the expression of proliferative and survival factors such 
as IL6, VEGF and IGF1 [41]; and MM-derived Jagged1 
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and 2 play a crucial role in MM-induced osteolysis [66]. 
Currently, the relative antibodies have been generated and 
now are in preclinical studies [109].
Molecular drugs
In comparison to antibody-based drugs, molecular 
drugs are more easily deliverable. SAHM1 is a stapled 
peptide derived from Mastermind-like (MAML) protein, 
able to block the canonical Notch signaling and has a 
therapeutic potential in hematopoietic tumors, indeed it is 
able to induce apoptosis in MM and T-ALL cells [46, 110].
Recently, Kangsamaksin et al. developed new 
decoy peptides based on Notch1 EGF-like repeats fused 
to human IgGγ heavy chain (Fc). These decoys may 
selectively inhibit DLL4 or Jagged1 without affecting the 
signal mediated by other ligands. The authors showed their 
efficacy against melanoma, breast, lung and pancreatic 
cancer both in vitro and in vivo, including a significantly 
reduced renal, gastrointestinal and hepatic toxicity, 
compared to GSI treatment [100].
CONCLUSIONS
Current studies on Notch pathway in MM indicate 
that the dysregulated Notch receptors and ligands increase 
the activation of Notch signaling in MM cells promoting 
their progression and the ability to shape a supportive 
surrounding microenvironment. The contribution of 
aberrantly activated Notch signaling in drug resistance and 
development of MM associated bone disease provides a 
strong rational for a therapeutic approach in MM directed 
to control Notch activity in both malignant plasma cells 
and the surrounding BM stroma. In our opinion, among 
all the Notch-targeted therapeutic approaches available 
or in development, those specifically directed to Jagged1 
and 2 promise to be effective and prevent the side effects 
associated to GSIs.
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